Literature DB >> 29871380

Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors.

An De Groef1, Mira Meeus2, Tessa De Vrieze1, Lore Vos1, Marijke Van Kampen1, Inge Geraerts1, Nele Devoogdt1.   

Abstract

BACKGROUND: Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI).
OBJECTIVE: The aim was to determine prevalence rate of this feature and explore the treatment-, patient-, pain-, and psychosocial-related variables associated with the degree of self-reported signs of central sensitization, assessed with the CSI (0-100), in breast cancer survivors at long-term. STUDY
DESIGN: Cross-sectional study.
SETTING: University Hospitals, Leuven, Belgium.
METHODS: One hundred and forty-six women with persistent pain, more than one year after breast cancer surgery, were included. The following factors were analyzed by bivariable and multivariable analysis: 1) treatment-related variables (type of surgery, levels of lymph node dissected, radiotherapy, chemotherapy, hormone therapy, and trastuzumab); 2) patient's related variables (age and body mass index); 3) pain-related variables (pain intensity, pain quality, primary hyperalgesia, and index of widespread pain); and 4) psychosocial variables (the degree of pain catastrophizing and vigilance and awareness to pain). The dependent variable was degree of central sensitization measured with the CSI. Additionally, a stepwise regression was performed.
RESULTS: Fifty-five (38%) patients reported signs of central sensitization measured with the CSI (i.e., > 40/100). From multivariable analysis, it appears that more severe pain quality and higher levels of pain catastrophizing contribute to a higher degree of central sensitization. The stepwise regression revealed that up to 24% of variance of the CSI can be explained by these factors. LIMITATIONS: A selection bias may be present since patients were all recruited from a larger cohort participating in clinical trials on the effectiveness of physical therapy after breast cancer treatment.
CONCLUSION: Signs of central sensitization cannot be neglected in breast cancer survivors at long term. More severe pain quality and pain catastrophizing contribute to higher levels of central sensitization in this population. KEY WORDS: Breast neoplasm, pain, central sensitization mechanisms, central sensitization inventory.

Entities:  

Mesh:

Year:  2018        PMID: 29871380

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  4 in total

1.  A Subgroup of Chronic Low Back Pain Patients With Central Sensitization.

Authors:  Kosaku Aoyagi; Jianghua He; Andrea L Nicol; Daniel J Clauw; Patricia M Kluding; Stephen Jernigan; Neena K Sharma
Journal:  Clin J Pain       Date:  2019-11       Impact factor: 3.442

2.  Sensory signs and symptoms in women with self-reported breast cancer-related lymphedema: a case-control study close up.

Authors:  An De Groef; Nele Devoogdt; Ceren Gursen; Niamh Moloney; Victoria Warpy; Jolien Daelemans; Lore Dams; Vincent Haenen; Elien Van der Gucht; An-Kathleen Heroes; Tessa De Vrieze; Elizabeth Dylke
Journal:  J Cancer Surviv       Date:  2021-08-28       Impact factor: 4.062

3.  Colorectal cancer pain upon diagnosis and after treatment: a cross-sectional comparison with healthy matched controls.

Authors:  Maria Lopez-Garzon; Paula Postigo-Martin; Ángela González-Santos; Manuel Arroyo-Morales; Alexander Achalandabaso-Ochoa; Antonio Manuel Férnández-Pérez; Irene Cantarero-Villanueva
Journal:  Support Care Cancer       Date:  2022-01-13       Impact factor: 3.359

4.  Changes in Pain Sensitivity in Treatment for Breast Cancer: A 12-Month Follow-Up Case Series.

Authors:  Laura Lorenzo-Gallego; Beatriz Arranz-Martín; Helena Romay-Barrero; Virginia Prieto-Gómez; Enrique Lluch; María Torres-Lacomba
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.